Literature DB >> 14722170

Developmental pharmacokinetics of morphine and its metabolites in neonates, infants and young children.

N J Bouwmeester1, B J Anderson, D Tibboel, N H G Holford.   

Abstract

BACKGROUND: Descriptions of the pharmacokinetics and metabolism of morphine and its metabolites in young children are scant. Previous studies have not differentiated the effects of size from those related to age during infancy.
METHODS: Postoperative children 0-3 yr old were given an intravenous loading dose of morphine hydrochloride (100 micro g kg(-1) in 2 min) followed by either an intravenous morphine infusion of 10 micro g h(-1) kg(-1) (n=92) or 3-hourly intravenous morphine boluses of 30 micro g kg(-1) (n=92). Additional morphine (5 micro g kg(-1)) every 10 min was given if the visual analogue (VAS, 0-10) pain score was >/=4. Arterial blood (1.4 ml) was sampled within 5 min of the loading dose and at 6, 12 and 24 h for morphine, morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G). The disposition of morphine and formation clearances of morphine base to its glucuronide metabolites and their elimination clearances were estimated using non-linear mixed effects models.
RESULTS: The analysis used 1856 concentration observations from 184 subjects. Population parameter estimates and their variability (%) for a one-compartment, first-order elimination model were as follows: volume of distribution 136 (59.3) litres, formation clearance to M3G 64.3 (58.8) litres h(-1), formation clearance to M6G 3.63 (82.2) litres h(-1), morphine clearance by other routes 3.12 litres h(-1) per 70 kg, elimination clearance of M3G 17.4 (43.0) litres h(-1), elimination clearance of M6G 5.8 (73.8) litres h(-1). All parameters are standardized to a 70 kg person using allometric 3/4 power models and reflect fully mature adult values. The volume of distribution increased exponentially with a maturation half-life of 26 days from 83 litres per 70 kg at birth; formation clearance to M3G and M6G increased with a maturation half-life of 88.3 days from 10.8 and 0.61 litres h(-1) per 70 kg respectively at birth. Metabolite formation decreased with increased serum bilirubin concentration. Metabolite clearance increased with age (maturation half-life 129 days), and appeared to be similar to that described for glomerular filtration rate maturation in infants.
CONCLUSION: M3G is the predominant metabolite of morphine in young children and total body morphine clearance is 80% that of adult values by 6 months. A mean steady-state serum concentration of 10 ng ml(-1) can be achieved in children after non-cardiac surgery in an intensive care unit with a morphine hydrochloride infusion of 5 micro g h(-1) kg(-1) at birth (term neonates), 8.5 micro g h(-1) kg(-1) at 1 month, 13.5 micro g h(-1) kg(-1) at 3 months and 18 micro g h(-1) kg(-1) at 1 year and 16 micro g h(-1) kg(-1) for 1- to 3-yr-old children.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14722170     DOI: 10.1093/bja/aeh042

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  74 in total

1.  Pharmacogenetic testing: Current Evidence of Clinical Utility.

Authors:  Jivan Moaddeb; Susanne B Haga
Journal:  Ther Adv Drug Saf       Date:  2013-08-01

2.  ABCC3 and OCT1 genotypes influence pharmacokinetics of morphine in children.

Authors:  Raja Venkatasubramanian; Tsuyoshi Fukuda; Jing Niu; Tomoyuki Mizuno; Vidya Chidambaran; Alexander A Vinks; Senthilkumar Sadhasivam
Journal:  Pharmacogenomics       Date:  2014-07       Impact factor: 2.533

3.  A population pharmacokinetic model for montelukast disposition in adults and children.

Authors:  Rohini Ramakrishnan; Elizabeth Migoya; Barbara Knorr
Journal:  Pharm Res       Date:  2005-04-07       Impact factor: 4.200

Review 4.  Population clinical pharmacology of children: modelling covariate effects.

Authors:  Brian J Anderson; Karel Allegaert; Nicholas H G Holford
Journal:  Eur J Pediatr       Date:  2006-06-29       Impact factor: 3.183

5.  Limited predictability of amikacin clearance in extreme premature neonates at birth.

Authors:  Karel Allegaert; Brian J Anderson; Veerle Cossey; Nicholas H G Holford
Journal:  Br J Clin Pharmacol       Date:  2006-01       Impact factor: 4.335

6.  First dose in children: physiological insights into pharmacokinetic scaling approaches and their implications in paediatric drug development.

Authors:  Ashley Strougo; Thomas Eissing; Ashraf Yassen; Stefan Willmann; Meindert Danhof; Jan Freijer
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-02-05       Impact factor: 2.745

7.  Electronic Health Record-Embedded Decision Support Platform for Morphine Precision Dosing in Neonates.

Authors:  Alexander A Vinks; Nieko C Punt; Frank Menke; Eric Kirkendall; Dawn Butler; Thomas J Duggan; DonnaMaria E Cortezzo; Sam Kiger; Tom Dietrich; Paul Spencer; Rob Keefer; Kenneth D R Setchell; Junfang Zhao; Joshua C Euteneuer; Tomoyuki Mizuno; Kevin R Dufendach
Journal:  Clin Pharmacol Ther       Date:  2019-12-11       Impact factor: 6.875

8.  Reduced Exposure to Piperaquine, Compared to Adults, in Young Children Receiving Dihydroartemisinin-Piperaquine as Malaria Chemoprevention.

Authors:  Meghan E Whalen; Richard Kajubi; Nona Chamankhah; Liusheng Huang; Francis Orukan; Erika Wallender; Moses R Kamya; Grant Dorsey; Prasanna Jagannathan; Philip J Rosenthal; Norah Mwebaza; Francesca T Aweeka
Journal:  Clin Pharmacol Ther       Date:  2019-07-22       Impact factor: 6.875

Review 9.  Pharmacologic management of the opioid neonatal abstinence syndrome.

Authors:  Walter K Kraft; John N van den Anker
Journal:  Pediatr Clin North Am       Date:  2012-08-30       Impact factor: 3.278

Review 10.  Psychoactive drug exposure during breastfeeding: a critical need for preclinical behavioral testing.

Authors:  Irving Zucker
Journal:  Psychopharmacology (Berl)       Date:  2018-03-16       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.